This article is from the source 'bbc' and was first published or seen on . It will not be checked again for changes.

You can find the current article at its original source at http://news.bbc.co.uk/go/rss/-/1/hi/uk/7282627.stm

The article has changed 2 times. There is an RSS feed of changes available.

Version 0 Version 1
Gaviscon maker 'cheated the NHS' Gaviscon maker 'cheated the NHS'
(about 16 hours later)
The makers of Gaviscon maintained an effective monopoly on the market for years after the stomach medicine came off patent, Newsnight has been told.The makers of Gaviscon maintained an effective monopoly on the market for years after the stomach medicine came off patent, Newsnight has been told.
Internal documents show Reckitt Benckiser executives schemed to create obstacles to block rival manufacturers from selling cheap generic copies.Internal documents show Reckitt Benckiser executives schemed to create obstacles to block rival manufacturers from selling cheap generic copies.
A former senior executive said Reckitt had "cheated the NHS" and could have saved it "millions of pounds".A former senior executive said Reckitt had "cheated the NHS" and could have saved it "millions of pounds".
Reckitt said it was a responsible firm which behaved honestly and ethically.Reckitt said it was a responsible firm which behaved honestly and ethically.
Newsnight was told Reckitt sold Gaviscon to the NHS for three times the cost of generic drugs.Newsnight was told Reckitt sold Gaviscon to the NHS for three times the cost of generic drugs.
Executives also boasted that they had influenced regulatory bodies to delay the introduction of a generic name for Gaviscon.Executives also boasted that they had influenced regulatory bodies to delay the introduction of a generic name for Gaviscon.
Should we not drag it out as long as possible... nine million pounds of business is at stake E-mail by Reckitt executive We are shocked by the allegations made as Reckitt Benckiser is a responsible company Reckitt Benckiser Healthcare UK class="" href="/1/hi/programmes/newsnight/7284030.stm">Read company's statement
The generic name should have been published in 2000 but Reckitt objected.The generic name should have been published in 2000 but Reckitt objected.
The same happened again in 2003 and Reckitt made further objections in 2005 and 2006.The same happened again in 2003 and Reckitt made further objections in 2005 and 2006.
In each case it cited health and patient safety as the reason for its objections but the secret internal documents tell a different story.In each case it cited health and patient safety as the reason for its objections but the secret internal documents tell a different story.
One Reckitt executive wrote: "Should we not drag it out as long as possible... nine million pounds of business is at stake".One Reckitt executive wrote: "Should we not drag it out as long as possible... nine million pounds of business is at stake".
'Smoking guns'
Others wrote of their intention to create "a further barrier to competitors" and "restrict entry for new competitors" by abusing the regulatory process.Others wrote of their intention to create "a further barrier to competitors" and "restrict entry for new competitors" by abusing the regulatory process.
Should we not drag it out as long as possible... nine million pounds of business is at stake E-mail by Reckitt executive
John Schmidt, a competition lawyer from Shepherd and Wedderburn, has examined some of the e-mails and business plans which were supposed to be shredded.John Schmidt, a competition lawyer from Shepherd and Wedderburn, has examined some of the e-mails and business plans which were supposed to be shredded.
He told Newsnight they raised the question of whether Reckitt had been in breach of competition law.He told Newsnight they raised the question of whether Reckitt had been in breach of competition law.
He said there were "smoking guns in the e-mails so I would be very surprised if the Office of Fair Trading wasn't interested".He said there were "smoking guns in the e-mails so I would be very surprised if the Office of Fair Trading wasn't interested".
While the delaying tactics continued, Reckitt persuaded doctors to switch patients to a form of Gaviscon which was still under patent.While the delaying tactics continued, Reckitt persuaded doctors to switch patients to a form of Gaviscon which was still under patent.
The techniques they used to do this were sometimes questionable.The techniques they used to do this were sometimes questionable.
The pharmaceutical companies' own trade body - the ABPI - found that Reckitt had misled doctors and behaved unethically in its dealings with some GPs in Glasgow.The pharmaceutical companies' own trade body - the ABPI - found that Reckitt had misled doctors and behaved unethically in its dealings with some GPs in Glasgow.
Patient carePatient care
Reckitt says this was an unfortunate one-off incident.Reckitt says this was an unfortunate one-off incident.
Nine years after its patent elapsed, Gaviscon still has 88% of the market for alginic acid compounds in the National Health Service and there is still no generic name.Nine years after its patent elapsed, Gaviscon still has 88% of the market for alginic acid compounds in the National Health Service and there is still no generic name.
Generic copies of Gaviscon could have saved around £40m from the drugs budget since 1999.Generic copies of Gaviscon could have saved around £40m from the drugs budget since 1999.
Parliament's health select committee is expected to investigate the Gaviscon case.Parliament's health select committee is expected to investigate the Gaviscon case.
Committee member and former doctor Richard Taylor MP said: "I have regular letters from people with cancer and other serious problems who cannot get the drugs and that's where we should be spending the money, rather than giving companies huge profits on drugs that aren't really an advance."Committee member and former doctor Richard Taylor MP said: "I have regular letters from people with cancer and other serious problems who cannot get the drugs and that's where we should be spending the money, rather than giving companies huge profits on drugs that aren't really an advance."
Reckitt Benckiser told Newsnight it was a responsible company which behaved honestly and ethically at all times and that, from the outset, patient care and safety has driven all its actions.Reckitt Benckiser told Newsnight it was a responsible company which behaved honestly and ethically at all times and that, from the outset, patient care and safety has driven all its actions.
It said it had never objected to a generic name being published, "the timetable of which is not within our control".It said it had never objected to a generic name being published, "the timetable of which is not within our control".
However, it also expressed concern at what it called "the inappropriate sentiment" in some of the internal correspondence of 2003 and would be taking action.However, it also expressed concern at what it called "the inappropriate sentiment" in some of the internal correspondence of 2003 and would be taking action.
Newsnight's investigation of Gaviscon will be broadcast at 2230 GMT on Friday 7 March on BBC Two.Newsnight's investigation of Gaviscon will be broadcast at 2230 GMT on Friday 7 March on BBC Two.